<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510783</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00002266</org_study_id>
    <nct_id>NCT00510783</nct_id>
    <nct_alias>NCT00832858</nct_alias>
  </id_info>
  <brief_title>IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures</brief_title>
  <official_title>IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at three seizure medicines. Patients with seizures are usually treated
      with phenytoin (Dilantin) or Fosphenytoin. These medicines can be given intravenously (IV)or
      by mouth. Another seizure medicine, levetiracetam (Keppra) can now be given this way also.
      This study will compare IV phenytoin (Dilantin) and IV fosphenytoin to levetiracetam (Keppra)
      in patients who have had a recent seizure. Only patients with a history of seizures can be
      involved. The patient must present to the emergency department within 4 hours of a seizure.
      The purpose of this study is to compare these three drugs, phenytoin (Dilantin),
      fosphenytoin, and levetiracetam (Keppra). The investigators are looking to see if these drugs
      can prevent another seizure in the next 24 hours. We are also looking for any possible side
      effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than one in every one hundred patients presenting to the emergency department for care
      do so for seizures. More than half of these patients will require medications, often
      intravenously (IV), while in the emergency department. For many years the standard treatment
      has been phenytoin. However, there are many known contraindications to the use of this drug.
      These include known hypersensitivity, cardiac arrhythmias, cardiac disease, impaired liver or
      kidney function, diabetes mellitus, older age, thyroid disease, pregnancy, and alcohol use. A
      recent review of patients with seizure disorder at Emory Crawford Long and Emory University
      hospitals suggested that a significant percentage of those who were taking phenytoin actually
      had one or more of these contraindications. Additionally, the IV form of phenytoin has known,
      severe adverse effects including cardiovascular collapse, life threatening cardiac
      arrhythmias, and severe hypotension. There is another form of Phenytoin, called Fosphenytoin,
      that while safer in some respects still has similar concerns associated with its
      administration.

      Levetiracetam (Keppra) has been available as an oral drug in the United States since 2000 and
      has a well established safety record when used as an add-on drug for patients with partial
      onset seizures. A double-blinded randomized study has shown that levetiracetam is also
      effective for primary generalized seizures as well.

      The IV form of levetiracetam has recently been approved by the FDA for use. The only known
      contraindications other than known hypersensitivity include impaired renal function,
      psychiatric disorder, older age, and pregnancy. IV levetiracetam is not known to cause any of
      the acute, catastrophic events seen occasionally with phenytoin.

      The investigators would therefore like to compare IV phenytoin and fosphenytoin to IV
      levetiracetam in preventing early recurrent seizures. Patients with known seizure disorders
      would be randomly assigned to one of two groups and therefore receive either IV fosphenytoin
      or IV levetiracetam. After an observation period, seizure free patients would be discharged
      and 24 hour phone follow up conducted to assess for the effectiveness of these anti-seizure
      medications as well as for any adverse reactions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced a Recurrent Seizure After Treatment.</measure>
    <time_frame>24 hours</time_frame>
    <description>Recurrent seizure is defined as a seizure within 24 hours of treatment in the Emergency Department.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Tonic-clonic Seizure</condition>
  <arm_group>
    <arm_group_label>Phenytoin/Fosphenytoin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keppra</intervention_name>
    <description>The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <other_name>levetiracetam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosphenytoin</intervention_name>
    <description>IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.</description>
    <arm_group_label>Phenytoin/Fosphenytoin</arm_group_label>
    <other_name>Cerebyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilantin</intervention_name>
    <description>IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.</description>
    <arm_group_label>Phenytoin/Fosphenytoin</arm_group_label>
    <other_name>phenytoin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or older

          -  patient presenting to Grady Memorial Hospital's Emergency Department after having a
             tonic-clonic seizure (primary or secondarily generalized) within the last 4 hours

        Cause of seizure for inclusion: reason for seizure is often undetermined at time of
        presentation to the Emergency Department. The most likely expected causes of a seizure are
        noncompliance to existing antiepileptic drug regimen, refractory epilepsy with breakthrough
        seizure, metabolic aberration, alcohol withdrawal, or unknown.

        Exclusion Criteria:

          -  non-English speaking

          -  first time seizure

          -  seizures other than tonic-clonic seizure (primary or secondarily generalized)

          -  more than 3 seizures in 24 hours or status epilepticus, pregnant patients by history
             or by urine pregnancy testing, serious neurologic insult resulting in seizure but
             where seizure is not the primary reason for admission (e.g. traumatic brain injury
             with seizure or hemorrhagic stoke would be excluded)

          -  contraindication to IV levetiracetam

          -  received IV phenytoin within 24 hours

          -  known allergy to phenytoin

          -  previously enrolled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Houry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2007</study_first_submitted>
  <study_first_submitted_qc>July 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2007</study_first_posted>
  <results_first_submitted>January 8, 2011</results_first_submitted>
  <results_first_submitted_qc>July 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2013</results_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Debra Houry, MD, MPH</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>tonic-clonic seizure</keyword>
  <keyword>emergency department</keyword>
  <keyword>IV levetiracetam</keyword>
  <keyword>Keppra</keyword>
  <keyword>seizures</keyword>
  <keyword>phenytoin</keyword>
  <keyword>Dilantin</keyword>
  <keyword>Grand Mal seizure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Fosphenytoin</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study completed</recruitment_details>
      <pre_assignment_details>study completed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phenytoin/Fosphenytoin</title>
          <description>Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).</description>
        </group>
        <group group_id="P2">
          <title>Levetiracetam</title>
          <description>Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenytoin/Fosphenytoin</title>
          <description>Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).</description>
        </group>
        <group group_id="B2">
          <title>Levetiracetam</title>
          <description>Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.80" spread="106.459"/>
                    <measurement group_id="B2" value="65.79" spread="154.721"/>
                    <measurement group_id="B3" value="58.53" spread="131.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced a Recurrent Seizure After Treatment.</title>
        <description>Recurrent seizure is defined as a seizure within 24 hours of treatment in the Emergency Department.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenytoin/Fosphenytoin</title>
            <description>Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced a Recurrent Seizure After Treatment.</title>
          <description>Recurrent seizure is defined as a seizure within 24 hours of treatment in the Emergency Department.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phenytoin/Fosphenytoin</title>
          <description>Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).</description>
        </group>
        <group group_id="E2">
          <title>Levetiracetam</title>
          <description>Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Burning at the IV Site</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Several patients were lost to follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Brittney Copeland</name_or_title>
      <organization>Emory</organization>
      <phone>404-616-0301</phone>
      <email>bcopel3@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

